References
- Goadsby P. J., Hoskin K. L. Inhibition of trigeminal neurones by intravenous administration of the serotonin (5HT) 1B/D agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine. Pain 1996; 67: 355–3591. Goadsby P. J., Hoskin K. L. Inhibition of trigeminal neurones by intravenous administration of the serotonin (5HT) 1B/D agonist zolmitriptan (311C90): are brain stem sites therapeutic targets in migraine. Pain 1996; 67: 355–359
- Martin G. Pre-clinical pharmacology of zolmitriptan (Zomig™, formerly 311C90), a centrally and peripherally acting 5HTIB/ID agonist for migraine. Cephalalgia 1997; 17: 4–14, (Suppl 18)2. Martin G. Pre-clinical pharmacology of zolmitriptan (ZomigTM, formerly 311C90), a centrally and peripherally acting 5HTIB/ID agonist for migraine. Cephalalgia 1997; 17: 4–14, (Suppl 18)
- Dixon R., Warrander A. The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997; 17: 15–20, (Suppl 18)3. Dixon R., Warrander A. The clinical pharmacokinetics of zolmitriptan. Cephalalgia 1997; 17: 15–20, (Suppl 18)
- Rapoport A. M., Ramadan N. M., Adelman J. U., Mathew N. T., Elkind A. H., Kudrow D. B., Earl N. L. Optimising the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. Neurology 1997; 49: 1210–12184. Rapoport A. M., Ramadan N. M., Adelman J. U., Mathew N. T., Elkind A. H., Kudrow D. B., Earl N. L. Optimising the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. Neurology 1997; 49: 1210–1218
- Schoenen J., Sawyer J. Zolmitriptan (Zomig™, 311C90), a novel dual central and peripheral 5HTIB/ID agonist: an overview of efficacy. Cephalalgia 1997; 17: 28–40, (Suppl 18)5. Schoenen J., Sawyer J. Zolmitriptan (ZomigTM, 311C90), a novel dual central and peripheral 5HTIB/ID agonist: an overview of efficacy. Cephalalgia 1997; 17: 28–40, (Suppl 18)
- The International 311C90 Long-Term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (‘Zomig’, 311C90). An international study. Headache 1998; 38: 173–1836. The International 311C90 Long-Term Study Group. The long-term tolerability and efficacy of oral zolmitriptan (‘Zomig’, 311C90). An international study. Headache 1998; 38: 173–183
- Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8: 1–96, (Suppl 7)7. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8: 1–96, (Suppl 7)
- Edmeads J., Millson D. S. Tolerability profile of zolmitriptan (Zomig™; 311C90), a novel dual central and peripheral 5HTIB/ID agonist. Cephalalgia 1997; 17: 41–52, (Suppl 18)8. Edmeads J., Millson D. S. Tolerability profile of zolmitriptan (ZomigTM; 311C90), a novel dual central and peripheral 5HTIB/ID agonist. Cephalalgia 1997; 17: 41–52, (Suppl 18)
- Simmons V. E., Blakeborough P. The safety profile of sumatriptan. Reviews in Contemporary Pharmacotherapy 1994; 5: 319–3289. Simmons V. E., Blakeborough P. The safety profile of sumatriptan. Reviews in Contemporary Pharmacotherapy 1994; 5: 319–328